Ginkgo biloba prophylaxis for acute mountain sickness

Ginkgo biloba prophylaxis for acute mountain sickness, a randomized controlled clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001412

Enrollment

Unknown

Registered

2011-07-05

Start date

2011-06-28

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute mountain sickness

Interventions

1:Acetazolamide

2:Ginkgo biloba

3:Placebo

Eligibility

Sex/Gender

Male

Age

18 Years to 22 Years

Inclusion criteria

Inclusion criteria: (1) Altitude of residence lower than or equal to 900m; (2) Never climb to the altitude above 1500m in the last two years.

Exclusion criteria

Exclusion criteria: (1) Obesity; (2) Lung, heart dysfunction; (3) Liver, kidney dysfunction; (4) Hypertension; (5) Anemia, coagulation disorder; (6) Allergy to sulfonamides; (7) Taking methazolamide or acetazolamide or any drugs used to prevent acute mountain sickness within one week before the initiation of the trial.

Design outcomes

Primary

Measure	Time frame
Acute mountain sickness;	—

Secondary

Measure	Time frame
Middle cerebral artery blood flow velocity;Heart rate, Blood pressure, Arterial oxygen saturation;	—

Countries

China

Contacts

Public ContactWen Jing, Luo

luowenj@fmmu.edu.cn+86 029 84774863

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026